Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5238_Библиотеки_им_академика_М_И_Перельмана.pdf
6 Antidepressants inPregnancy
129
Risks of Untreated Depression Untreated depression during pregnancy can lead
to signicant risks, including preterm birth, low birth weight, fetal growth restriction, miscarriage, macrosomia, preeclampsia, poor prenatal care, and long-term
developmental challenges in the child, such as cognitive, behavioral, and emotional
disorders, attention-decit/hyperactivity disorder, and delayed socioemotional and
linguistic development.
SSRIs and Birth Defects SSRIs are associated with an increased risk of congenital malformations, particularly cardiac defects, which necessitates further research
to determine safe usage during pregnancy.
Neonatal Risks The use of SSRIs and other antidepressants during pregnancy can
lead to potential risks, including congenital malformations, preterm birth, low birth
weight, neonatal adaptation issues, and long-term developmental challenges in the
child, such as cognitive, behavioral, and emotional disorders, while untreated maternal depression itself poses additional risks like miscarriage, fetal growth restriction,
and developmental delays.
Role of Timing in Exposure The timing of antidepressant exposure during pregnancy (rst, second, or third trimester) plays a notable role in determining the associated risks, highlighting the need for tailored treatment plans.
Pharmacokinetic Changes in Pregnancy Pregnancy-induced physiological
changes, including altered metabolism and hormone levels, affect how antidepressants are absorbed and metabolized, requiring careful dose adjustments.
Benets of Treating Maternal Depression The benets of treating maternal
depression during pregnancy, such as preventing relapse and promoting better overall health, outweigh the risks of medication when managed properly.
Confounding Factors in Research
The relationship between antidepressant use
and adverse outcomes is often confounded by maternal depression itself, making it
challenging to isolate the effects of medications from the impact of untreated
depression.
Statistical Signicance Versus Clinical Signicance Statistically signicant
associations with outcomes like preterm birth and congenital malformations do not
always translate into clinically signicant impacts, as the actual risks to maternal
and fetal health may be small and context-dependent. Therefore, healthcare providers must consider both statistical and clinical signicance when making treatment
decisions, ensuring that the benets of medication outweigh the potential risks to
both the mother and child.
130
E. Yaz ıcı and Ö. A. Ciner
Careful Medication Management The decision to use antidepressants during
pregnancy must be carefully considered, taking into account both the benets of
treating maternal depression and the potential risks to fetal-maternal health.
Individualized Treatment Plans There is no one-size-ts-all approach to antide-
pressant use during pregnancy. Each treatment plan should be personalized, considering the severity of maternal depression, the type of antidepressant, and fetal safety.
Multidisciplinary Approach The management of a pregnancy with exposure to
antidepressants should involve a multidisciplinary team, including obstetricians,
psychiatrists, and pediatricians, to ensure the best outcomes for both the mother
and child.
Need for Ongoing Research Continued research is essential to rene our understanding of the risks and benets of antidepressant use during pregnancy, ensuring
that healthcare providers can make informed decisions based on the latest evidence.
References
Adina J, Morawska A, Mitchell AE, Haslam D, Ayuku D.Depression and anxiety in second and
third trimesters among pregnant women in Kenya: a hospital-based prevalence study. J Affect
Disord Rep. 2022;10:100447.
Alwan S, Friedman JM, Chambers C.Safety of selective serotonin reuptake inhibitors in preg-
nancy: a review of current evidence. CNS Drugs. 2016;30(6):499–515. https://doi.org/10.1007/
s40263- 016- 0338- 3.
Amit G, Yanover C, Bivas-Benita M, Girshovitz I, Helbitz T, Sudry T, etal. Antidepressant use dur-
ing pregnancy and the risk of preterm birth– a cohort study. NPJ Women’s Health. 2024;2(1):5.
https://doi.org/10.1038/s44294- 024- 00008- 0.
Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, etal. Maternal
use of specic antidepressant medications during early pregnancy and the risk of selected birth
defects. JAMA Psychiatry. 2020;77(12):1246–55.
Andrade C. Gestational exposure to antidepressant drugs and neurodevelopment: an examina-
tion of language, mathematics, intelligence, and other cognitive outcomes. J Clin Psychiatry.
2022;83(1) https://doi.org/10.4088/JCP.22f14388.
Ankarfeldt MZ, Petersen J, Andersen JT, Fernandes MFS, Li H, Motsko SP, etal. Duloxetine expo-
sure during pregnancy and the risk of spontaneous and elective abortion: a Danish Nationwide
observational study. Drugs Real World Outcomes. 2021a;8(3):289–99. https://doi.org/10.1007/
s40801- 021- 00252- 9.
Ankarfeldt MZ, Petersen J, Andersen JT, Li H, Motsko SP, Fast T, etal. Exposure to duloxetine
during pregnancy and risk of congenital malformations and stillbirth: a nationwide cohort
study in Denmark and Sweden. PLoS Med. 2021b;18(11):e1003851.
Ankarfeldt MZ, Petersen J, Andersen JT, Fernandes MFS, Li H, Motsko SP, et al. Duloxetine
exposure during pregnancy and the risk of offspring being born small for gestational age or
prematurely: a Nationwide Danish and Swedish safety study. Drugs Real World Outcomes.
2023;10(1):69–81.
Arulandoo A, Kugathasan S.Determining the severity of neonatal abstinence syndrome among
newborns exposed to selective serotonin reuptake inhibitors and serotonin and norepinephrine
reuptake inhibitors in utero: a protocol for a systematic review and meta-analysis. URNCST
J. 2023;7:1–6.
https://doi.org/10.1007/s40801- 022- 00334- 2.
6 Antidepressants inPregnancy
Avram M, Stika C, Rasmussen-Torvik L, Ciolino J, Pinheiro E, George A Jr, Wisner K.Rationale
and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for
pregnant women with depression. Clin Pharm Ther. 2016;100(1):31–3.
Bandoli G, Chambers CD, Wells A, Palmsten K.Prenatal antidepressant use and risk of adverse
neonatal outcomes. Pediatrics. 2020;146(1)
Benevent J, Araujo M, Karki S, Delarue-Hurault C, Waser J, Lacroix I, etal. Risk of hypertensive
disorders of pregnancy in women treated with serotonin-norepinephrine reuptake inhibitors: a
comparative study using the EFEMERIS database. J Clin Psychiatry. 2023;84(4):47872.
Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP.The risk of major cardiac mal-
formations associated with paroxetine use during the rst trimester of pregnancy: a systematic
review and meta-analysis. Br J Clin Pharmacol. 2016;81(4):589–604.
Bérard A, Sheehy O, Zhao JP, Vinet É, Bernatsky S, Abrahamowicz M.SSRI and SNRI use dur-
ing pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br J Clin
Pharmacol. 2017;83(5):1126–33.
Bérard A, Levin M, Sadler T, Healy D. Selective serotonin reuptake inhibitor use during preg-
nancy and major malformations: the importance of serotonin for embryonic development
and the effect of serotonin inhibition on the occurrence of malformations. Bioelectricity.
2019;1(1):18–29.
Bernard N, Forest J-C, Tarabulsy GM, Bujold E, Bouvier D, Giguère Y.Use of antidepressants
and anxiolytics in early pregnancy and the risk of preeclampsia and gestational hypertension: a
prospective study. BMC Pregnancy Childbirth. 2019;19:1–9.
Bliddal M, Wesselhoeft R, Strandberg-Larsen K, Ernst MT, Weissman MM, Gingrich JA,
etal. Prenatal antidepressant exposure and emotional disorders until age 22: a danish reg-
ister study. Child Adolesc Psychiatry Ment Health. 2023;17(1):73. https://doi.org/10.1186/
s13034- 023- 00624- 9.
Bobo WV, Moore KM, Betcher HK, Larish AM, Stoppel CM, VandeVoort JL, etal. The Association
of Antidepressants in late pregnancy with postpartum hemorrhage: systematic review of con-
trolled observational studies. J Child Adolesc Psychopharmacol. 2024;34(10):428–46. https://
doi.org/10.1089/cap.2024.0085.
Bobula B, Bąk J, Kania A, Siwiec M, Kiełbiński M, Tokarski K, etal. Maternal uoxetine impairs
synaptic transmission and plasticity in the medial prefrontal cortex and alters the structure
and function of dorsal raphe nucleus neurons in offspring mice. Pharmacol Biochem Behav.
2024;244:173849. https://doi.org/10.1016/j.pbb.2024.173849.
Brajcich MR, Palau MA, Messer RD, Murphy ME, Marks J.Why the maternal medication list
matters: neonatal toxicity from combined serotonergic exposures. Pediatrics. 2021;147(2)
https://doi.org/10.1542/peds.2019- 2250.
Cabrera RM, Linda Lin Y, Law E, Kim J, Wlodarczyk BJ.The teratogenic effects of sertraline in
mice. Birth Defects Res. 2020;112(13):1014–24. https://doi.org/10.1002/bdr2.1660.
Cafaro R, Giorgetti F, Giacovelli L, Vanzetto S, Cerolini L, Colombo A, Dell’Osso B.Analyses of
pharmacokinetic, Pharmacogenetic and psychometrics correlates of antidepressants use during
pregnancy and the post-partum period. Eur Psychiatry. 2022;65(S1):S234.
Campbell SC, Salisbury LM, Roberts JK, Kamyar M, Fredrickson J, Costantine MM, Sherwin
CM.Therapeutic drug monitoring in pregnancy. In: Clinical challenges in therapeutic drug
monitoring. Elsevier; 2016. p.185–211.
Chan JKN, Lee KCK, Wong CSM, Chang WC.Prenatal antidepressant use and risk of congenital
malformations: a population-based cohort study. Psychiatry Res. 2024;339:116038.
Chang Q, Ma X-Y, Xu X-R, Su H, Wu Q-J, Zhao Y-H.Antidepressant use in depressed women
during pregnancy and the risk of preterm birth: a systematic review and meta-analysis of 23
cohort studies. Front Pharmacol. 2020;11:659.
Chen LF, Lin CE, Chung CH, Lai CH, Chien WC.Association between the use of antidepres-
sants and the risk of preterm birth among pregnant women with depression: a retrospec-
tive cohort study in Taiwan. J Investig Med. 2021;69(5):999–1007. https://doi.org/10.1136/
jim- 2020- 001683.
131
132
Christensen J, Trabjerg BB, Sun Y, Dreier JW. Association of Maternal Antidepressant
Prescription during Pregnancy with Standardized Test Scores of Danish school-aged children.
JAMA. 2021;326(17):1725–35. https://doi.org/10.1001/jama.2021.17380.
Combellick JL, Esmaeili A, Johnson AM, Haskell SG, Phibbs CS, Manzo L, Miller LJ.Perinatal
mental health and pregnancy-associated mortality: opportunities for change. Arch Womens
Ment Health. 2024;27(3):417–24.
Cornet M-C, Wu YW, Forquer H, Avalos LA, Sriram A, Schefer AW, etal. Maternal treatment
with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation:
a population-based cohort study. Arch Dis Child Fetal Neonatal Ed. 2024;109(3):294–300.
Cristina D.Woman and pregnancy: focus on depression and psychopharmacological therapy. Int J
Basic Clin Pharm. 2023;12(2):284–90.
Dama MH, Van Lieshout RJ.Perinatal depression: a guide to detection and management in pri-
mary care. J Am Board Family Med. 2023;36(6):1071–86.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E.A systematic review and meta-analy-
sis considering the SSRI, SNRI and TCA classes of antidepressants and the risk for congenital
heart defects; 2020. medRxiv, 2020.2002. 2024.20027532.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E.A systematic review and meta-analy-
sis considering the risk for congenital heart defects of antidepressant classes and individual anti-
depressants. Drug Saf. 2021a;44(3):291–312.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E.A systematic review and meta-anal-
ysis considering the risk for congenital heart defects of antidepressant classes and individual
antidepressants. Drug Saf. 2021b;44:291–312.
Desaunay P, Eude L-G, Dreyfus M, Alexandre C, Fedrizzi S, Alexandre J, et al. Benets and
risks of antidepressant drugs during pregnancy: a systematic review of meta-analyses. Pediatr
Drugs. 2023;25(3):247–65.
Desaunay P, Eslier M, Alexandre J, Dreyfus M, Chrétien B, Guenolé F. Antidepressants and
fetal death: a systematic review and disproportionality analysis in the WHO safety database
(VigiBase®). Psychiatry Res. 2024;339:116048.
Di Vincenzo M, Ferrandino M, Sollo V, Landol L, Mancuso E, Di Cerbo A, etal. Antenatal
depression, obstetric outcomes, and post-partum depression: results from a longitudinal, real-
world study. Eur Psychiatry. 2023;66(S1):S501–2.
Dodeja P, Chaphekar N, Caritis SN, Venkataramanan R. Optimizing drug therapy during preg-
nancy: a spotlight on population pharmacokinetic modeling. Expert Opin Drug Metab Toxicol.
2025;21(2):143–60. https://doi.org/10.1080/17425255.2024.2420195.
Domingues RR, Beard AD, Connelly MK, Wiltbank MC, Hernandez LL.Fluoxetine-induced peri-
natal morbidity in a sheep model. Front Med. 2022;9:955560.
Domingues RR, Wiltbank MC, Hernandez LL.Maternal serotonin: implications for the use of
selective serotonin reuptake inhibitors during gestation. Biol Reprod. 2023;109(1):17–28.
https://doi.org/10.1093/biolre/ioad046.
Dubiel-Hoppanova L etal. Pregestational stress representing a maternal depression model and
prenatally applied antidepressant mirtazapine modulate hippocampal excitability in the off-
spring; 2025.
Dubovicky M, Belovicova K, Csatlosova K, Bogi E.Risks of using SSRI/SNRI antidepressants
during pregnancy and lactation. Interdiscip Toxicol. 2017;10(1):30–4. https://doi.org/10.1515/
intox- 2017- 0004.
Einarson A, Choi J, Einarson TR, Koren G.Incidence of major malformations in infants follow-
ing antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J
Psychiatr. 2009;54(4):242–6. https://doi.org/10.1177/070674370905400405.
Eke AC.An update on the physiologic changes during pregnancy and their impact on drug phar-
macokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol. 2022;33(5):581–98.
https://doi.org/10.1515/jbcpp- 2021- 0312.
Ekhart C, van Hunsel F, van Puijenbroek E, Chandler R, Meldau E-L, Taavola H, Norén GN.Post-
marketing safety prole of vortioxetine using a cluster analysis and a disproportionality analy-
sis of global adverse event reports. Drug Saf. 2022;45(2):145–53.
https://doi.org/10.1007/s00737- 023- 01404- 2.
https://doi.org/10.1007/s40264- 020- 01027- x.
E. Yaz ıcı and Ö. A. Ciner
6 Antidepressants inPregnancy
Ergun B, etal. Effects of prenatal and lactational vortioxetine exposure on emotional states, motor
activities and cognitive performances of offspring. Psychiatry Behav Sci. 2024;14(3)
Fabiano N, Wong S, Gupta A, Tran J, Bhambra N, Min KK, etal. Safety of psychotropic med-
ications in pregnancy: an umbrella review. Mol Psychiatry. 2025;30(1):327–35. https://doi.
org/10.1038/s41380- 024- 02697- 0.
Febrianti Y.Antidepressant use in pregnancy and the risk of neonatal outcomes: a scoping review.
Jurnal Ilmiah Farmasi. 2024;20(1):90–102.
Fitton C, Steiner M, Aucott L, Pell J, Mackay D, Fleming M, McLay J.In utero exposure to anti-
depressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr
Scand. 2020;141(1):21–33.
Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, etal. Selective serotonin
reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: popula-
tion based cohort study and sibling design. BMJ. 2015;350:h1798. https://doi.org/10.1136/
bmj.h1798.
Galbally M, Watson SJ, Spigset O.Depression and antidepressant treatment in the development
of hypertensive disorders of pregnancy: results from a prospective cohort study. Aust N Z J
Psychiatry. 2023;57(4):520–7.
Galletta MAK, Tess VLC, Pasotti IM, Pelegrini LF, Ribeiro Rocha NK, Testa CB, Francisco
RPV. Use of mirtazapine and olanzapine in the treatment of refractory hyperemesis gravi-
darum: a case report and systematic review. Case Rep Obstet Gynecol. 2022;2022(1):7324627.
Gallitelli V, Franco R, Guidi S, Puri L, Parasiliti M, Vidiri A, etal. Depression treatment in
pregnancy: is it safe, or is it not? Int J Environ Res Public Health. 2024;21(4) https://doi.
org/10.3390/ijerph21040404.
Gao S-Y, Wu Q-J, Sun C, Zhang T-N, Shen Z-Q, Liu C-X, etal. Selective serotonin reuptake
inhibitor use during early pregnancy and congenital malformations: a systematic review and
meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018;16(1):205.
https://doi.org/10.1186/s12916- 018- 1193- 5.
Gastaldon C, Arzenton E, Raschi E, Spigset O, Papola D, Ostuzzi G, etal. Neonatal withdrawal
syndrome following in utero exposure to antidepressants: a disproportionality analysis of
VigiBase, the WHO spontaneous reporting database. Psychol Med. 2023a;53(12):5645–53.
Gastaldon C, Arzenton E, Raschi E, Spigset O, Papola D, Ostuzzi G, etal. Pharmacovigilance
analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to anti-
depressants. Eur Psychiatry. 2023b;66(Suppl 1):S96.
Glazova NY, Merchieva S, Volodina M, Sebentsova E, Manchenko D, Kudrun V, Levitskaya
N.Effects of neonatal uvoxamine administration on the physical development and activity of
the serotoninergic system in white rats. Acta Nat. 2014;6(3):98–105.
Goracci A, Valdagno M, Maltinti E, Sillari S, Fagiolini A. Antidepressant use in pregnancy:
a critical review of the risk and benets. Riv Psichiatr. 2015;50(3):118–26. https://doi.
org/10.1708/1910.20792.
Gram MA, Laksafoss A, Hviid A. Antidepressant exposure patterns during pregnancy and risk
of adverse newborn outcomes. Psychiatry Res. 2024;342:116274. https://doi.org/10.1016/j.
psychres.2024.116274.
Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis C-L, et al.
Antidepressant exposure during pregnancy and congenital malformations: is there an asso-
ciation? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry.
2013;74(4):903.
Haq MIU, Fatima S, Amjad N, Sheikh JR.Impact of maternal depression on pregnancy and neo-
natal outcomes: a prospective analysis: maternal stress and neonatal outcomes. Pak J Health
Sci. 2024:02–7.
Heerdink ER.Antidepressants and postpartum haemorrhage. Br Med J. 2013;347:f5194. https://
doi.org/10.1136/bmj.f5194.
Heuvelman H etal. Antidepressants in pregnancy: applying causal epidemiological methods to
understand service-use outcomes in women and long-term neurodevelopmental outcomes in
exposed children; 2023.
133
134
Hosseini K, Cediel-Ulloa A, Al-Sabri MH, Forsby A, Fredriksson R.Assessing the neurodevelop-
mental impact of uoxetine, citalopram, and paroxetine on neural stem cell-derived neurons.
Pharmaceuticals. 2024;17(10):1392.
Huybrechts KF, Bateman BT, Pawar A, Bessette LG, Mogun H, Levin R, etal. Maternal and fetal
outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ. 2020;368
Hwang YM et al. Timing of selective serotonin reuptake inhibitor use and risk for preterm
birth and related adverse events; 2023. medRxiv, 2023.2003. 2003.23286717.
Jahan N, Went TR, Sultan W, Sapkota A, Khurshid H, Qureshi IA, Alfonso M.Untreated depres-
sion during pregnancy and its effect on pregnancy outcomes: a systematic review. Cureus.
2021;13(8):e17251. https://doi.org/10.7759/cureus.17251.
Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Lander AR, Afzal S, et al. SSRI
use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry.
2013;170(3):299–304.
Karnwal R, Sharmila K. Perspective view of stress, anxiety, and depression among pregnant
women: a review. J Ecophysiol Occup Health. 2024:7–19.
Kautzky A, Slamanig R, Unger A, Höich A. Neonatal outcome and adaption after in utero
exposure to antidepressants: a systematic review and meta-analysis. Acta Psychiatr Scand.
2022;145(1):6–28.
Kent ME, Hu B, Eggleston TM, Squires RS, Zimmerman KA, Weiss RM, etal. Hypersensitivity of
zebrash htr2b mutant embryos to sertraline indicates a role for serotonin signaling in cardiac
development. J Cardiovasc Pharmacol. 2022;80(2):261–9.
Kieviet N, Duijn M, Dolman K, Honig A.Poor neonatal adaptation after in utero exposure to u-
voxamine. J Obstet Gynaecol. 2015;35(2):201–2.
Kiribayashi M, Suda T, Takahashi M, Ishikawa M, Watanabe R, Ishioka K, etal. Vortioxetine
exposure during pregnancy and lactation: a Japanese case study of neonatal implications and
quantitative Milk and plasma analyses. Breastfeed Med. 2024;19(8):659–62.
Knopf A.Pregnant women may benet from continued use of antidepressants. Brown Univ Child
Adolesc Psychopharm Update. 2023;25(6):5.
Koc D, Tiemeier H, Stricker BH, Muetzel RL, Hillegers M, El Marroun H.Prenatal antidepressant
exposure and offspring brain morphologic trajectory. JAMA Psychiatry. 2023;80(12):1208–17.
https://doi.org/10.1001/jamapsychiatry.2023.3161.
Kolding L, Henriksen JN, Pedersen LH.Fetal cardiac safety of sertraline use during pregnancy.
Expert Opin Drug Saf. 2023;22(8):653–7.
Lam YF. Antidepressant use patterns in pregnancy. Brown Univ Psychopharm Update.
2023;34(8):2–3.
Lassen D, Ennis ZN, Damkier P. First-trimester pregnancy exposure to venlafaxine or dulox-
etine and risk of major congenital malformations: a systematic review. Basic Clin Pharmacol
Toxicol. 2016;118(1):32–6. https://doi.org/10.1111/bcpt.12497.
Laurent L, Huang C, Ernest SR, Berard A, Vaillancourt C, Hales BF.In utero exposure to ven-
lafaxine, a serotonin–norepinephrine reuptake inhibitor, increases cardiac anomalies and
alters placental and heart serotonin signaling in the rat. Birth Defects Res A Clin Mol Teratol.
2016;106(12):1044–55.
Lee M-J, Chen Y-L, Wu S-I, Huang C-W, Dewey ME, Chen VC-H.Association between maternal
antidepressant use during pregnancy and the risk of autism spectrum disorder and attention
decit hyperactivity disorder in offspring. Eur Child Adolesc Psychiatry. 2024;33:1–11.
Levy M, Kovo M, Miremberg H, Anchel N, Herman HG, Bar J, etal. Maternal use of selective
serotonin reuptake inhibitors (SSRI) during pregnancy– neonatal outcomes in correlation with
placental histopathology. J Perinatol. 2020;40(7):1017–24.
Liao T, Gao Y, Yang X, Tang Y, Wang B, Yang Q, etal. Preconception depression reduces fertility:
a couple-based prospective preconception cohort. Hum Reprod Open. 2024;2024(3):hoae032.
Lou Z-Q, Zhou Y-Y, Zhang X, Jiang H-Y.Exposure to selective noradrenalin reuptake inhibitors
during the rst trimester of pregnancy and risk of congenital malformations: a meta-analysis of
cohort studies. Psychiatry Res. 2022;316:114756.
E. Yaz ıcı and Ö. A. Ciner
6 Antidepressants inPregnancy
Maligireddy A, Jabri A, Zghouzi M, Rojulpote C, VanAken G, Janga C, etal. Maternal and fetal
outcomes in pulmonary hypertension during pregnancy: a contemporary Nationwide analysis.
Am J Cardiol. 2024;221:113–9. https://doi.org/10.1016/j.amjcard.2024.04.016.
Maloney SE etal. Maternal SSRI treatment during offspring development results in long-term
behavioral, cellular, and neuroimaging disruptions2017. bioRxiv, 205708.
Marks C, Quinney S, Haas D.Comparing newborn outcomes after prenatal exposure to individual
antidepressants. Proc IMPRS. 2020;3(1)
Martin FZ, Smith S, Rai D, Forbes H.Antidepressant use during pregnancy and risk of stillbirth: a
systematic review and meta-analysis. Reprod Female Child Health. 2023;2(3):177–87.
Martin FZ etal. Antidepressant use during pregnancy and birth outcomes: analysis of electronic
health data from the UK, Norway, and Sweden; 2024. medRxiv.
Milosavljević JZ, Milosavljević MN, Arsenijević PS, Milentijević MN, Stefanović SM.The effects
of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review.
Int J Psychiatry Clin Pract. 2022;26(1):43–9. https://doi.org/10.1080/13651501.2021.1872647.
Mitchell J, Goodman J. Comparative effects of antidepressant medications and untreated
major depression on pregnancy outcomes: a systematic review. Arch Womens Ment Health.
2018;21(5):505–16.
Murad F.A prospective cohort study to assess neonatal adaptation in neonates exposed to psycho-
tropic medications in utero. Br J Psych Open. 2022;8(S1):S62.
Nagandla K, Nalliah S, Yin LK, Majeed ZA, Ismail M, Zubaidah S, etal. Prevalence and associ-
ated risk factors of depression, anxiety and stress in pregnancy. Int J Reprod Contracept Obstet
Gynecol. 2017;5(7):2380–8.
Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K.Neonatal morbidity after maternal
use of antidepressant drugs during pregnancy. Pediatrics. 2016;138(5)
Nunes TP, Nunes LP, Silva ANA, Pirovani BO, Morábito MJSD, de Morais LA, etal. Effects adverse
of treatment with selective inhibitors of serotonin recaptation on the fetus and neonatals of
mothers with gestational depression: a critical review. Res Soc Dev. 2021;10(4):e11210413937.
https://doi.org/10.33448/rsd- v10i4.13937.
Ogunyemi D, Jovanovski A, Liu J, Friedman P, Sugiyama N, Creps J, Madan I.The contribution of
untreated and treated anxiety and depression to prenatal, intrapartum, and neonatal outcomes.
AJP Rep. 2018;08(03):e146–57.
Okagbue HI, Adamu PI, Bishop SA, Oguntunde PE, Opanuga AA, Akhmetshin EM.Systematic
review of prevalence of antepartum depression during the trimesters of pregnancy. Open Access
Maced J Med Sci. 2019;7(9):1555–60. https://doi.org/10.3889/oamjms.2019.270.
Olivier JD, Åkerud H, Kaihola H, Pawluski JL, Skalkidou A, Högberg U, Sundström Poromaa
I.The effects of maternal depression and maternal selective serotonin reuptake inhibitor expo-
sure on offspring. Front Cell Neurosci. 2013;7 https://doi.org/10.3389/fncel.2013.00073.
Ornoy A, Koren G. Selective serotonin reuptake inhibitors during pregnancy: do we have now
more denite answers related to prenatal exposure? Birth Defects Res. 2017;109(12):898–908.
https://doi.org/10.1002/bdr2.1078.
Ornoy A, Koren G.SSRIs and SNRIs (SRI) in pregnancy: effects on the course of pregnancy and
the offspring: how far are we from having all the answers? Int J Mol Sci. 2019;20(10):2370.
Ostenfeld A, Petersen TS, Pedersen LH, Westergaard HB, Løkkegaard ECL, Andersen
JT. Mirtazapine exposure in pregnancy and fetal safety: a nationwide cohort study. Acta
Psychiatr Scand. 2022;145(6):557–67. https://doi.org/10.1111/acps.13431.
Ostenfeld A, Lyngholm S, Christensen SE, Petersen TS, Andersen JT, Westergaard HB, etal.
Mirtazapine in pregnancy and lactation: a systematic review of adverse outcomes. Acta
Psychiatr Scand. 2025;151(1):6–32. https://doi.org/10.1111/acps.13749.
Oswald M, El-Chaar G, Canter M.Hypothermia as a presenting sign of venlafaxine-induced neo-
natal abstinence syndrome in 2 neonates. J Pediatr Pharm Ther. 2024;29(6):654–9.
Padilla-Azain MC, Osmundson SS, Bosworth O, Wiese A, Pham A, Leech AA, etal. Opioid anal-
gesic and antidepressant use during pregnancy and the risk of spontaneous preterm birth: a
nested case–control study. Paediatr Perinat Epidemiol. 2024;
https://doi.org/10.1007/s00737- 018- 0844- z.
https://doi.org/10.18203/2320- 1770.ijrcog20162132.
https://doi.org/10.1055/s- 0038- 1661379.
135
136
Palmsten K, Hernández-Díaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, etal. Use
of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income
women in the United States. Br Med J. 2013;347:f4877. https://doi.org/10.1136/bmj.f4877.
Parpinel G, Rosso G, Galante A, Germano C, Aragno E, Girlando F, etal. Effect of depressive
disorders and their pharmacological treatment during pregnancy on maternal and neonatal out-
come. J Clin Med. 2022;11(6):1486.
Poweleit EA, Cinibulk MA, Novotny SA, Wagner-Schuman M, Ramsey LB, Strawn JR.Selective
serotonin reuptake inhibitor pharmacokinetics during pregnancy: clinical and research implica-
tions. Front Pharmacol. 2022;13:833217.
Rohanachandra YM.Depression in mothers and mental health in their children: impact, risk fac-
tors, and interventions. In: The neuroscience of depression. Elsevier; 2021. p.45–55.
Rommel A-S, Bergink V, Liu X, Munk-Olsen T, Molenaar NM.Long-term effects of intrauterine
exposure to antidepressants on physical, neurodevelopmental, and psychiatric outcomes: a sys-
tematic review. J Clin Psychiatry. 2020;81(3):10661.
Rommel A-S, Semark BD, Liu X, Madsen KB, Agerbo E, Munk-Olsen T, etal. Prenatal antidepres-
sant exposure and the risk of decreased gestational age and lower birthweight: a polygenic score
approach to investigate confounding by indication. Acta Psychiatr Scand. 2024;150(5):344–54.
https://doi.org/10.1111/acps.13636.
Rotem-Kohavi N, Goodman SH, Wazana A, Oberlander TF.The other side of prenatal depression:
developmental outcomes associated with antidepressant medication therapy. Prenatal Stress
and Child Development; 2021, p.565–593.
Roy R, Chakraborty M, Bhattacharya K, Roychoudhury T, Mukherjee S. Impact of perinatal
maternal depression on child development. Indian J Psychiatry. 2022;64(3):284–8.
Salkeld E, Ferris LE, Juurlink DN.The risk of postpartum hemorrhage with selective serotonin
reuptake inhibitors and other antidepressants. J Clin Psychopharmacol. 2008;28(2):230.
Santos RA, Sousa AP, Almeida-Santos T, Ramalho-Santos J, Tavares RS.In vitro effects of antide-
pressants on human sperm function. Asian J Androl. 2025;27(1):30–6.
Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA.The impact of
pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-
analysis. Expert Opin Drug Metab Toxicol. 2020;16(5):431–40.
Shea AK, Wang DY, Snelgrove JW, Dalfen A, Hewko S, Murphy KE.Do maternal pharmacoge-
netics impact the neonatal abstinence syndrome following in utero exposure to antidepres-
sant medications? J Obstet Gynaecol Can. 2021;43(6):726–32. https://doi.org/10.1016/j.
jogc.2020.09.026.
Sheftel C, Sartori LC, Manuel R, Fricke H, Bell A, Mulvenna E, Hernandez LL.MON-001 peri-
partum sertraline (Zoloft®) increases pup mortality immediately postpartum. J Endocr Soc.
2020;4(Supplement_1) https://doi.org/10.1210/jendso/bvaa046.1840.
Shen Z-Q, Gao S-Y, Li SX, Zhang T-N, Liu C-X, Lv H-C, etal. Sertraline use in the rst trimester
and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. Br J
Clin Pharmacol. 2017;83(4):909–22. https://doi.org/10.1111/bcp.13161.
Shweiki S, Diav-Citrin O.Pregnancy outcome after rst trimester exposure to vortioxetine: a case
series. Birth Defects Res. 2021;113(6):511–5.
Sivojelezova A.Fluvoxamine (LUVOX™) use in pregnancy. Clin Pharm Ther. 2004;75(2):P25.
https://doi.org/10.1016/j.clpt.2003.11.094.
Smithson J, Mitchell PB.Chapter 2– Antidepressants. In: Ray SD, editor. Side effects of drugs
annual, vol. 37. Elsevier; 2015. p.15–31.
Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective sero-
tonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality.
JAMA. 2013;309(1):48–54.
Suarez EA, Bateman BT, Hernández-Díaz S, Straub L, Wisner KL, Gray KJ, etal. Association of
antidepressant use during pregnancy with risk of neurodevelopmental disorders in children.
JAMA Intern Med. 2022;182(11):1149–60.
Sujan AC.What do we know about in-utero antidepressant exposure, and are these medications
safe to use during pregnancy? Acta Psychiatr Scand. 2022;145:541–3.
E. Yaz ıcı and Ö. A. Ciner
6 Antidepressants inPregnancy
Sun Y, Dreier JW, Liu X, Glejsted Ingstrup K, Mægbæk ML, Munk-Olsen T, Christensen J.Trend
of antidepressants before, during, and after pregnancy across two decades– a population-based
study. Brain and behavior. 2019;9(11):e01441.
Sun M, Zhang S, Li Y, Chen L, Diao J, Li J, etal. Effect of maternal antidepressant use during the
pre-pregnancy/early pregnancy period on congenital heart disease: a prospective cohort study
in Central China. Front Cardiovasc Med. 2022;9:916882.
Svensson M, Reimers A, Reis M. Pharmacokinetics of antidepressants during pregnancy.
Lakartidningen. 2020;117:FYLY.
Tanguay N, Abdelouahab N, Simard M-N, Séguin JR, Marc I, Herba CM, etal. Antidepressants
use during pregnancy and child psychomotor, cognitive and language development at 2 years
of age– results from the 3D cohort study. Front Pharmacol. 2023;14:1252251.
Tharp MA, Silvola RM, Marks C, Teal E, Quinney SK, Haas DM. Does lack of exposure to
individual antidepressants at different points during pregnancy associate with reduced risk
of adverse newborn outcomes? BMC Pregnancy Childbirth. 2022;22(1):926. https://doi.
org/10.1186/s12884- 022- 05287- 6.
The Medical Letter. Addendum: bupropion safety in pregnancy. Med Lett Drugs Ther.
2024;66(1699):56. https://doi.org/10.58347/tml.2024.1699c.
Uguz F. Is there any association between use of antidepressants and preeclampsia or gesta-
tional hypertension?: a systematic review of current studies. J Clin Psychopharmacol.
2017;37(1):72–7.
Uguz F.The use of antidepressant medications during pregnancy and the risk of neonatal seizures:
a systematic review. J Clin Psychopharmacol. 2019;39(5):479–84.
Uguz F.Neonatal and childhood outcomes in offspring of pregnant women using antidepressant
medications: a critical review of current meta-analyses. J Clin Pharmacol. 2021;61(2):146–58.
https://doi.org/10.1002/jcph.1724.
Urato AC.Are the SSRI antidepressants safe in pregnancy? Understanding the debate. Int J Risk
Safety Med. 2015;27(2):93–9.
Ushkalova E, Ushkalova A. Comparative analysis of the use of selective serotonin reuptake
inhibitors during pregnancy and the postpartum period. Safety of sertraline. Neuro Npsy Psyc.
2023;15(5):94–101.
Vartiainen E etal. Pre-and postnatal maternal depressive symptoms associate with local connectiv-
ity of the left amygdala in 5-year-olds; 2024. bioRxiv, 2024.2006. 2021.600007.
Velasquez JC, Goeden N, Herod SM, Bonnin A.Maternal pharmacokinetics and fetal disposition
of (±)-citalopram during mouse pregnancy. ACS Chem Neurosci. 2016;7(3):327–38.
Verma A, Kumar A.Risks associated with vortioxetine in the established therapeutic indication.
Curr Neuropharmacol. 2021;19(5):711–7.
Vigod SN, Frey BN, Clark CT, Grigoriadis S, Barker LC, Brown HK, etal. Clinical practice
guideline for the Management of Perinatal Mood, anxiety, and related disorders: guide de pra-
tique 2024 du Canadian network for mood and anxiety treatments pour le traitement des trou-
bles de l’humeur, des troubles anxieux et des troubles connexes périnatals. Can J Psychiatry.
2024;70:07067437241303031. https://doi.org/10.1177/07067437241303031.
Viguera AC, McElheny SA, Caplin PS, Kobylski LA, Rossa ET, Young AV, etal. Risk of poor neo-
natal adaptation syndrome among infants exposed to second-generation atypical antipsychot-
ics compared to antidepressants: results from the National Pregnancy Registry for psychiatric
medications. J Clin Psychiatry. 2023;84(1) https://doi.org/10.4088/JCP.22m14492.
Wang J, Cosci F. Neonatal withdrawal syndrome following late in utero exposure to selective
serotonin reuptake inhibitors: a systematic review and meta-analysis of observational studies.
Psychother Psychosom. 2021;90(5):299–307. https://doi.org/10.1159/000516031.
Wartko PD, Weiss NS, Enquobahrie DA, Chan KG, Stephenson-Famy A, Mueller BA, Dublin
S. Association of antidepressant continuation in pregnancy and infant birth weight. J Clin
Psychopharmacol. 2021;41(4):403–13.
Weaver SR, Xie C, Charles JF, Hernandez LL. In utero and lactational exposure to the selec-
tive serotonin reuptake inhibitor uoxetine compromises pup bones at weaning. Sci Rep.
2019;9(1):238.
https://doi.org/10.1038/s41598- 018- 36497- 8.
137
138
Wemakor A, Casson K, Garne E, Bakker M, Addor M-C, Arriola L, etal. Selective serotonin
reuptake inhibitor antidepressant use in rst trimester pregnancy and risk of specic congenital
anomalies: a European register-based study. Eur J Epidemiol. 2015;30(11):1187–98. https://
doi.org/10.1007/s10654- 015- 0065- y.
Xing D, Wu R, Chen L, Wang T.Maternal use of antidepressants during pregnancy and risks for
adverse perinatal outcomes: a meta-analysis. J Psychosom Res. 2020;137:110231. https://doi.
org/10.1016/j.jpsychores.2020.110231.
Yang K, Qin X, Wang H, Zhou W.Exploring genetic causal relationship between antidepressants
use and congenital malformations. Reprod Toxicol. 2024;130:108736.
Yazıcı E, Şahin S.Psychiatric disorders during pregnancy and postpartum period: a guide for peri-
natal interview. Eur J Med. 2023;55(1):S61.
Yazici E, Kirkan TS, Aslan PA, Aydin N, Yazici AB.Untreated depression in the rst trimes-
ter of pregnancy leads to postpartum depression: high rates from a natural follow-up study.
Neuropsychiatr Dis Treat. 2015;11:405–11.
Yue M, Kus L, Katta S, Su I, Li L, Haas DM, Quinney SK.Pharmacokinetics of antidepressants in
pregnancy. J Clin Pharmacol. 2023;63:S137–58.
Zakiyah N, Ter Heijne LF, Bos JH, Hak E, Postma MJ, Schuiling-Veninga CC.Antidepressant use
during pregnancy and the risk of developing gestational hypertension: a retrospective cohort
study. BMC Pregnancy Childbirth. 2018;18:1–11.
Zeszutek S.Antidepressant use in pregnancy. In: Side effects of drugs annual, vol. 43. Elsevier;
2021. p.503–12.
E. Yaz ıcı and Ö. A. Ciner